Results 211 to 220 of about 10,941,841 (309)
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source
Corrigendum to "Ellagic acid through attenuation of neuro-inflammatory response exerted antidepressant-like effects in socially isolated mice" [Heliyon Volume 9, Issue 4, April 2023, Article e15550]. [PDF]
Mazrooei Z +5 more
europepmc +1 more source
TREX1, a predator for treating MSI‐H tumors?
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya +2 more
wiley +1 more source
Erratum to "Extrarenal Clinical Features are Reported for Most Genes Implicated in Genetic Kidney Disease" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1196-1204]. [PDF]
Serrano B, Savige J.
europepmc +1 more source
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Erratum to "Patient and Provider Attitudes Toward Patient-Facing Kidney Organ Offer Reporting" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1122-1130]. [PDF]
Husain SA +7 more
europepmc +1 more source
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source

